Abbott Laboratories Inc. announced July 10 that Japan’s Ministry of Health, Labor and Welfare has approved its Xience Xpeditition everolimus-eluting coronary stent with the broadest size matrix of any drug-eluting stent available in the Japanese market, including a unique 3.25 mm diameter. The approval is supported by data on the Xience platform from more than 53,000 patients across more than 100 studies, including five studies of more than 3,000 patients in Japan implanted with either Xience V or Xience Prime, according to Abbott
Xience Xpedition earned a CE mark in August 2012. (See [A#01120827005].) It gained FDA approval in January 2013. A...